Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Abstract

<jats:title>Abstract</jats:title> <jats:p>Objective To evaluate the efficacy and safety of PLD in treating of in patients with epithelial ovarian, tubal, and peritoneal cancer progression within 12 months after the first-line platinum-based therapy. Methods This was an open-label, single-arm and multicenter clinical trial. ORR was the interim primary objective and DCR, AEs and QOL were the secondary objectives. The impact of factors on the efficacy outcomes, the change trend of CA125 and the artificial platinum-free interval were exploratory endpoints. Results Totally, 115 patients were enrolled in this study and included in the ITT. Moreover, 101 patients were included in the safety analysis. The median follow-up time was 4 months (IQR 2–6). In ITT, the confirmed ORR was 37.4% (95%CI, 28.4%-46.4%), and the DCR was 65.2% (95%CI, 56.4%-74.1%). The previous response status to platinum-based chemotherapy and baseline CA125 levels were statistically correlated with the ORR. The ORR was significantly higher in the patients with a CA125 decrease after the first cycle than in the patients with a CA125 increase. The most common grade 3 or higher AE was hand-foot syndrome (3 [3.0%] of 101 patients). No statistically significant differences existed between the baseline and the postbaseline questionnaires. Conclusions For patients with platinum-resistant and platinum refractory relapse, the use of PLD may be a favorite choice because of the associated satisfactory efficacy, low frequency of AEs and high patient QOL. Moreover, a lower CA125 level at baseline and a reduction in CA125 after the first cycle are predictive factors for a better efficacy.</jats:p>

Biphasic JNK–Erk Signaling Separates Induction and Maintenance of Cell Senescence after DNA Damage

“…To examine whether the roles of JNK and Erk signaling in driving DDIS were unique to U2OS cells, similar studies were performed in OVCAR-8 high-grade serous ovarian cancer cells, a tumor type that is treated clinically with doxorubicin in the refractory or recurrent setting (Muggia et al, 1997; Yuan et al, 2021). Based on dose-response studies (Fig.…”

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer

“…As a single-agent therapy, PLD manifested survival similar to other agents and was well tolerated. PLD monotherapy as first-line chemotherapy for platinum-resistant or -refractory recurrent ovarian cancer, and clinical recommend using PLD at a dose of 40 mg/m 2 every 4 weeks as the initial dose [7][8][9].…”

Multidimensional imaging reveals mechanisms controlling label-free biosensing in vertical 2DM-heterostructures

“…In this work, correlated multidimensional imaging, including Raman and near-field microscopies, scanning probe and electron microscopies, was applied to unveil physical processes behind label-free multimodal detection of doxorubicin (DOX), an anthracycline cancer drug, by 2DM vertical heterostructures. Doxorubicin is one of the most common drugs against different types of cancer (haematological, thyroid, breast, ovarian, lung and liver cancer) [19][20][21][22][23] . Since DOX is known for certain drug resistance and side effects [24][25][26][27] , an efficient and sensitive detection of the amount of DOX in various types of biological samples, potentially at the point-of-care, has significant value.…”